Amol A. Kulkarni
Associate ProfessorChemistry and Biochemistry
MinerAlert
Dr. Kulkarni's research focuses on the design and synthesis of natural product-inspired small molecule inhibitors of the NLRP3 inflammasome. The Nod-like receptor, leucine-rich repeat protein-3 (NLRP3) inflammasome, plays a crucial role in the pathophysiology of neuroinflammation-associated disorders, such as Alzheimer’s disease, vascular dementia, Huntington’s disease, and HIV-associated neurocognitive disorders (HAND). His research employs a combination of classical and computational techniques for the design of novel compounds with potent and selective NLRP3 inhibitory activity, low toxicity, good oral bioavailability, and penetration into the blood-brain barrier. Dr. Kulkarni is also interested in the development of novel compounds for an HIV cure and the management of HIV-associated comorbidities. He earned a doctoral degree in chemistry from The State University of New York at Buffalo and both a master’s and bachelor’s in pharmaceutical chemistry from the University of Mumbai. Dr. Kulkarni is a member of the American Chemical Society and the American Association of Colleges of Pharmacy. His research has been funded by two R21 awards from the National Institute of Neurological Disorders and Stroke (NINDS), the National Institutes of Health (NIH), and two administrative supplements from NIMHD and NIH. While at HU, Dr. Kulkarni received the Professor of the Year Award and the Faculty of the Year Award multiple times. He has been the recipient of the Keystone Symposia Fellowship which provides training, mentorship, and career development opportunities for researchers from underrepresented backgrounds. He was recently appointed as the associate editor for the Springer journal Inflammation. During his downtime, Dr. Kulkarni enjoys reading and listening to music.
Dr. Kulkarni's research focuses on the design and synthesis of natural product-inspired small molecule inhibitors of the NLRP3 inflammasome. The Nod-like receptor, leucine-rich repeat protein-3 (NLRP3) inflammasome, plays a crucial role in the pathophysiology of neuroinflammation-associated disorders, such as Alzheimer’s disease, vascular dementia, Huntington’s disease, and HIV-associated neurocognitive disorders (HAND). His research employs a combination of classical and computational techniques for the design of novel compounds with potent and selective NLRP3 inhibitory activity, low toxicity, good oral bioavailability, and penetration into the blood-brain barrier. Dr. Kulkarni is also interested in the development of novel compounds for an HIV cure and the management of HIV-associated comorbidities. He earned a doctoral degree in chemistry from The State University of New York at Buffalo and both a master’s and bachelor’s in pharmaceutical chemistry from the University of Mumbai. Dr. Kulkarni is a member of the American Chemical Society and the American Association of Colleges of Pharmacy. His research has been funded by two R21 awards from the National Institute of Neurological Disorders and Stroke (NINDS), the National Institutes of Health (NIH), and two administrative supplements from NIMHD and NIH. While at HU, Dr. Kulkarni received the Professor of the Year Award and the Faculty of the Year Award multiple times. He has been the recipient of the Keystone Symposia Fellowship which provides training, mentorship, and career development opportunities for researchers from underrepresented backgrounds. He was recently appointed as the associate editor for the Springer journal Inflammation. During his downtime, Dr. Kulkarni enjoys reading and listening to music.
No info available.
No info available.
No info available.
No info available.